107 results
Page 2 of 6
8-K
vzh9vjqgrzcw51
26 Jun 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
EX-99.1
wkmdqn1i
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.2
tt8 hpes2
5 Jun 23
Results of Operations and Financial Condition
8:05am
424B5
e1wtkykv
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-99.1
ivbz2
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am
8-K
EX-99.1
rakwg6 95
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
ipzoq
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
424B5
77c0xsfaqjct7xe1 3q
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
fd89zgr
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-99.2
y7jdip02fvhn18
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.1
ax7 z7bv1
13 Sep 22
Regulation FD Disclosure
9:07am
424B5
0z01peuc0 ql
16 Jun 22
Prospectus supplement for primary offering
6:52am
8-K
EX-99.1
q4ppdvs78amljoh63eyh
8 Jun 22
Regulation FD Disclosure
9:06am
8-K
2ug1tzh e5w
3 Jun 22
Submission of Matters to a Vote of Security Holders
4:06pm